AML is Labeled Refractory After 2 Cycles of Induction Chemotherapy
AML is considered refractory (primary induction failure) when persistent disease remains after 2 courses of intensive induction therapy, which includes an initial induction cycle plus one reinduction attempt based on midcycle bone marrow assessment. 1
The Standard Definition
The most authoritative and recent guidelines establish this clearly:
After standard-dose cytarabine induction: Bone marrow assessment occurs at days 14-21. If significant residual disease is present without hypoplasia, a second cycle (reinduction) is administered. Patients with persistent disease after these 2 courses are labeled as having primary induction failure 1
After high-dose cytarabine induction: Assessment occurs at days 21-28. If significant residual disease persists without hypocellular marrow, the patient is considered to have induction failure, as additional HiDAC is unlikely to induce remission 1
The European LeukemiaNet definition: Primary induction failure is explicitly defined as failure to achieve complete remission after 2 courses of intensive induction chemotherapy 1, 2
The Clinical Algorithm
First Induction Cycle (Day 0)
- Administer standard "7+3" regimen or alternative intensive induction
- Perform bone marrow biopsy on days 14-21 (standard-dose) or 21-28 (high-dose cytarabine) 1
Midcycle Assessment Decision Points
If significant residual disease WITHOUT hypoplasia:
- Administer second induction cycle (reinduction) with same or escalated regimen 1
- This counts as part of the initial "course of therapy" for defining refractoriness 3
If >50% cytoreduction with low residual blasts:
- Continue with standard reinduction dosing 1
If hypoplastic marrow:
- Defer treatment until remission status can be assessed 1
After Second Cycle (Reinduction)
- If persistent disease remains: Patient is NOW labeled as refractory/primary induction failure 1
- Likelihood of achieving CR with a third chemotherapy regimen drops to approximately 20% 1
Important Caveats and Nuances
The "Two Cycles" Must Be Properly Administered
The definition assumes both cycles were appropriately intensive. If the protocol includes a predetermined second induction attempt for patients with persistent disease after the first attempt, the two cycles together are considered the "initial course of treatment" for defining refractoriness 3. This is not simply giving two random cycles—it's a planned strategy with midcycle assessment.
Alternative Definitions Exist for Specific Contexts
The older ESMO guidelines state patients "failing to respond to one or two cycles" are considered refractory 4, but this is less precise than the current standard. The most rigorous contemporary definition requires the full 2-cycle approach with proper midcycle assessment 1.
Timing Matters for Relapsed Disease
For patients who achieve initial CR but relapse, different criteria apply:
- Early relapse within 6-12 months of first remission may be considered refractory disease 5
- Second and subsequent relapses are also classified as refractory 5
Prognosis Implications
Research shows conflicting data on whether requiring 2 cycles versus 1 cycle to achieve CR affects long-term outcomes. One large ECOG study found similar prognosis regardless 6, while more recent data suggests inferior survival for patients requiring 2 cycles 7. However, for the definition of refractoriness, what matters is persistent disease AFTER both cycles, not simply requiring 2 cycles to achieve remission.
What Happens After Refractory Label
Once labeled as refractory after 2 cycles:
- Clinical trial enrollment is the preferred option 1
- Salvage chemotherapy regimens for relapsed/refractory disease may be used 1
- Allogeneic stem cell transplantation should be explored if a donor is available 1, 2
- The chance of cure with conventional chemotherapy alone is minimal 2
Bottom line: The threshold is 2 complete courses of intensive induction therapy (initial induction + one reinduction attempt based on midcycle marrow assessment). This represents the standard across NCCN 1, ELN 2, 8, and international consensus guidelines 3.